This educational activity is intended for European medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, and other oncology healthcare professionals interested and/or involved in the treatment of patients with NSCLC.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

• Evaluate lung cancer biomarkers to inform choice of treatment strategy for NSCLC, including optimal methods for tissue sampling, analysis, and evaluation of results
• Identify the role of immunotherapy in lung cancer, in particular the role of checkpoint inhibition, and evaluate efficacy and safety of these treatments in NSCLC
• Adopt a multidisciplinary approach for the care of patients with lung cancer
• Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer
• Recognise the emerging treatment options for squamous cell NSCLC in order to provide best care for patients with these forms of lung cancer